Logo image of ESLA

ESTRELLA IMMUNOPHARMA INC (ESLA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ESLA - US2975841048 - Common Stock

0.994 USD
+0.02 (+2.47%)
Last: 1/16/2026, 8:10:12 PM
0.96 USD
-0.03 (-3.42%)
After Hours: 1/16/2026, 8:10:12 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to ESLA. ESLA was compared to 528 industry peers in the Biotechnology industry. Both the profitability and financial health of ESLA have multiple concerns. ESLA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ESLA has reported negative net income.
  • ESLA had a negative operating cash flow in the past year.
  • In the past 5 years ESLA always reported negative net income.
  • ESLA had a negative operating cash flow in each of the past 5 years.
ESLA Yearly Net Income VS EBIT VS OCF VS FCFESLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • ESLA's Return On Assets of -383.16% is on the low side compared to the rest of the industry. ESLA is outperformed by 92.99% of its industry peers.
Industry RankSector Rank
ROA -383.16%
ROE N/A
ROIC N/A
ROA(3y)-188.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESLA Yearly ROA, ROE, ROICESLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

  • ESLA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ESLA Yearly Profit, Operating, Gross MarginsESLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ESLA has been increased compared to 1 year ago.
  • ESLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ESLA Yearly Shares OutstandingESLA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
ESLA Yearly Total Debt VS Total AssetsESLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -29.31, we must say that ESLA is in the distress zone and has some risk of bankruptcy.
  • ESLA's Altman-Z score of -29.31 is on the low side compared to the rest of the industry. ESLA is outperformed by 86.55% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -29.31
ROIC/WACCN/A
WACCN/A
ESLA Yearly LT Debt VS Equity VS FCFESLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • A Current Ratio of 0.15 indicates that ESLA may have some problems paying its short term obligations.
  • With a Current ratio value of 0.15, ESLA is not doing good in the industry: 93.75% of the companies in the same industry are doing better.
  • ESLA has a Quick Ratio of 0.15. This is a bad value and indicates that ESLA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.15, ESLA is doing worse than 93.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
ESLA Yearly Current Assets VS Current LiabilitesESLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

  • The earnings per share for ESLA have decreased strongly by -55.40% in the last year.
EPS 1Y (TTM)-55.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 77.03% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-132.85%
EPS Next 2Y-90.91%
EPS Next 3Y-67.6%
EPS Next 5Y77.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ESLA Yearly Revenue VS EstimatesESLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
ESLA Yearly EPS VS EstimatesESLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ESLA. In the last year negative earnings were reported.
  • Also next year ESLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ESLA Price Earnings VS Forward Price EarningsESLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ESLA Per share dataESLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • A cheap valuation may be justified as ESLA's earnings are expected to decrease with -67.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-90.91%
EPS Next 3Y-67.6%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ESLA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ESTRELLA IMMUNOPHARMA INC

NASDAQ:ESLA (1/16/2026, 8:10:12 PM)

After market: 0.96 -0.03 (-3.42%)

0.994

+0.02 (+2.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)N/A
Inst Owners1.97%
Inst Owner Change0%
Ins Owners2.12%
Ins Owner Change0%
Market Cap37.54M
Revenue(TTM)N/A
Net Income(TTM)-13.50M
Analysts82.86
Price Target16.32 (1541.85%)
Short Float %6.07%
Short Ratio2.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS-0.26
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -383.16%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -29.31
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-55.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.69%
EPS Next Y-132.85%
EPS Next 2Y-90.91%
EPS Next 3Y-67.6%
EPS Next 5Y77.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-503.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-503.13%
OCF growth 3YN/A
OCF growth 5YN/A

ESTRELLA IMMUNOPHARMA INC / ESLA FAQ

What is the ChartMill fundamental rating of ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to ESLA.


Can you provide the valuation status for ESTRELLA IMMUNOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to ESTRELLA IMMUNOPHARMA INC (ESLA). This can be considered as Overvalued.


How profitable is ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

ESTRELLA IMMUNOPHARMA INC (ESLA) has a profitability rating of 0 / 10.


What is the financial health of ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

The financial health rating of ESTRELLA IMMUNOPHARMA INC (ESLA) is 0 / 10.


What is the expected EPS growth for ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

The Earnings per Share (EPS) of ESTRELLA IMMUNOPHARMA INC (ESLA) is expected to decline by -132.85% in the next year.